NCT00970502 · OUTCOME

Locoregional Progression

Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer · Source last updated 2017-04-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: participants
Interval / dispersion: Not reported
Time frame: 20 months

What was measured

Patients with locoregional and/or distant progression

Groups in this outcome

Erlotinib + Celecoxib

erlotinib + celecoxib: In this phase I/II study, patients will be treated with daily erlotinib 150 mg and twice-daily celecoxib 200 to 600 mg for 14 days. Re-irradiation with IMRT will start on day 15 and will continue for 5.5 to 6.5 weeks along with erlotinib and celecoxib. After completion of radiation, patients will be given the option of continuing on erlotinib for 2 years or until unacceptable toxicity or disease progression

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Erlotinib + Celecoxib	14

Reported measurements

free of disease

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Erlotinib + Celecoxib	4	Not reported	Not reported	Not reported	Not reported

isolated locoregional progression

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Erlotinib + Celecoxib	4	Not reported	Not reported	Not reported	Not reported

isolated distant progression

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Erlotinib + Celecoxib	2	Not reported	Not reported	Not reported	Not reported

both locoregional and distant progression

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Erlotinib + Celecoxib	1	Not reported	Not reported	Not reported	Not reported

no evidence of disease, died of comorbid illness

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Erlotinib + Celecoxib	3	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
4
title
free of disease
categories
measurements
group Id
OG000
value
4
title
isolated locoregional progression
categories
measurements
group Id
OG000
value
2
title
isolated distant progression
categories
measurements
group Id
OG000
value
1
title
both locoregional and distant progression
categories
measurements
group Id
OG000
value
3
title
no evidence of disease, died of comorbid illness

denoms

counts
group Id
OG000
value
14
units
Participants

description

Patients with locoregional and/or distant progression

groups

description
erlotinib + celecoxib: In this phase I/II study, patients will be treated with daily erlotinib 150 mg and twice-daily celecoxib 200 to 600 mg for 14 days. Re-irradiation with IMRT will start on day 15 and will continue for 5.5 to 6.5 weeks along with erlotinib and celecoxib. After completion of radiation, patients will be given the option of continuing on erlotinib for 2 years or until unacceptable toxicity or disease progression
id
OG000
title
Erlotinib + Celecoxib

param Type

NUMBER

reporting Status

POSTED

time Frame

20 months

title

Locoregional Progression

type

SECONDARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice